Märkte und Analysen

Why we’re overweight healthcare

October 31, 2025

Lesezeit: 3:08 mins

In this video, BNY Investments Newton global income portfolio manager, Jon Bell discusses some of the reasons for overweighting healthcare despite the sector’s recent challenges.

Key points:

Demographics are driving rising healthcare spending and innovation remains crucial for managing costs and improving outcomes.
The BNY Mellon Global Equity Income strategy is at its highest-ever healthcare overweight, focusing on medical devices, equipment, hospitals and insurers.
As Covid claims decline, insurers have been able to raise prices to achieve margin gains.

2753750 Exp: 26 Januar 2026

Aktien

Beyond the grid: expanding the investment universe in global infrastructure

BNY Investments' investment strategists Brian Blongastainer and Carolina Ortega explain why they expect to see a major acceleration in global infrastructure spending over the next decade, driven by new investment opportunities fuelled by the growth in artificial intelligence (AI).

expanding-the-investment-universe-in-global-infrastructure-tile-580x325px

Artikel | Aktien

Beyond the grid: expanding the investment universe in global infrastructure

BNY Investments Newton’s investment strategists Brian Blongastainer and Carolina Ortega explain why they expect to see a major acceleration in global infrastructure spending over the next decade, driven by new investment opportunities fuelled by the growth in artificial intelligence (AI).

IFMH | Anleihen

Assessing Europe's labelled bond market

In this video, Fabien Collado, portfolio manager of the Responsible Horizons Euro Corporate Bond strategy, shares his thoughts on the evolution of labelled bonds in Europe and explains why robust due diligence is integral to spotting and validating opportunities

Artikel | Aktien

Novo Nordisk: rethinking the playbook

Direct-to-client (DTC) health platforms and personalized compounded treatments may become standard practice in the rapidly evolving obesity treatment market. Walter Scott investment analyst Dr Oriana Beaumont believes that Novo Nordisk’s recent changes will help position them to effectively compete in this exciting and vast market.